Increasing knowledge of the relationship between p53 and MDM2 has led to 
development of potential small molecule inhibitors useful for clinical studies. 
Herein, we discuss the patented (2006-2010) inhibitors of p53-MDM2 interaction. 
The anticancer agents discussed in this review belong to several different 
chemical classes including benzodiazepinediones, cis-imidazolines, oxindoles, 
spiro-oxindoles, and numerous miscellaneous groups. This review also provides 
comprehensive information on inhibitors of p53-MDM2 interaction that are 
currently being tested in clinical trials. It is important to note that many of 
the disclosed inhibitors need further validation to be considered as bona fide 
inhibitors of p53-MDM2 interaction and some will not be further considered for 
future studies. On the other hand, JNJ-26854165, a novel tryptamine derivative 
and RG7112, a cis-imidazoline representative have shown promising results in 
early phases of trials in cancer patients. AT-219, a spiroindolinone in late 
stage preclinical studies is a likely candidate to proceed into clinical trials. 
It remains to be seen how these inhibitors will perform in future clinical 
studies as single agents and in combination with the currently approved 
chemotherapeutic agents.